Safety, immunogenicity and risk–benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I–III clinical trials across regions

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Bache Emmanuel Bache, Martin P Grobusch, Selidji Todagbe Agnandji

Journal title: Future Microbiology

Journal number: 15/2

Journal publisher: Future Medicine Ltd.

Published year: 2020

Published pages: 85-106

DOI identifier: 10.2217/fmb-2019-0237

ISSN: 1746-0913